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Bone mineral density (BMD) is a highly heritable pre-
dictor of osteoporotic fracture. Genome-wide asso-
ciation studies (GWAS) for BMD have identified
dozens of associations; yet, the genes responsible
for most associations remain elusive. Here, we
used a bone co-expression network to predict causal
genes at BMD GWAS loci based on the premise that
genes underlying a disease are often functionally
related and functionally related genes are often co-
expressed. By mapping genes implicated by BMD
GWAS onto a bone co-expression network, we pre-
dicted and inferred the function of causal genes for
30 of 64 GWAS loci. We experimentally confirmed
that two of the genes predicted to be causal,SPTBN1
and MARK3, are potentially responsible for the
effects of GWAS loci on chromosomes 2p16.2 and
14q32.32, respectively. This approach provides a
roadmap for the dissection of additional BMD
GWAS associations. Furthermore, it should be appli-
cable to GWAS data for a wide range of diseases.
INTRODUCTION
Osteoporosis is ametabolic disease characterized by decreased
bone mineral density (BMD) and an increased risk of fracture
(Black and Rosen, 2016). In the U.S., osteoporosis affects over
12 million individuals and is directly responsible for 1.5 million
fractures annually at a cost of $17 billion (Gass and Dawson-
Hughes, 2006). Osteoporosis is, in large part, influenced by ge-
netic variation with fracture-related traits, such as BMD, being
among the most heritable disease-associated quantitative traits
(h2 > 0.50) (Liu et al., 2012b; Ralston and de Crombrugghe, 2006;
Ralston and Uitterlinden, 2010; Zheng et al., 2011). As a result, a
comprehensive understanding of the genetic basis of osteopo-
rosis is critical for the development of approaches for its treat-
ment and prevention.Cell Systems 4, 1–14, J
This is an open access article undOver the last decade, genome-wide association studies
(GWASs) have revolutionized the genetic analysis of complex
diseases by discovering thousands of loci for hundreds of dis-
eases and disease-related quantitative traits, including BMD
(Frazer et al., 2009). In 2012, the GEnetic Factors for OSteopo-
rosis Consortium (GEFOSII) conducted a meta-analysis of
lumbar spine (LSBMD) and femoral neck (FNBMD) BMD in
80,000 individuals and identified 64 independent BMD associ-
ations (Estrada et al., 2012). The loci identified byGEFOSII repre-
sent a wealth of information with the potential to reveal novel
genes and pathways that play important roles in bone biology
and inform drug discovery (Nelson et al., 2015). Yet, ‘‘unlocking’’
this information requires an intimate understanding of the causal
variants and genes underlying each locus and, to date, there has
not been a systematic functional characterization of BMDGWAS
loci.
One approach successfully used for causal gene prediction is
the integration of GWAS data and biological networks (Jia and
Zhao, 2014; Leiserson et al., 2013). A number of studies have
used biological networks (e.g., protein-protein interaction and
co-expression networks) to both predict causal genes at
GWAS loci and use GWAS data to pinpoint key networkmodules
in disease (for example, Califano et al., 2012; Farber, 2010, 2013;
Gustafsson et al., 2015; Huan et al., 2015; M€akinen et al., 2014).
The idea behind this approach is that groups of genes influencing
a complex disease are often functionally related and participate
in similar pathways or processes (e.g., the function of bone-
forming osteoblasts or bone-resorbing osteoclasts) and func-
tionally related genes are often co-expressed (Goh et al.,
2007). Biological networks provide a framework to reconstruct
pathways in an unbiasedmanner and bymapping genes located
in GWAS regions onto a biological network it is possible to
extract disease relevant pathways and causal genes. Co-
expression networks are particularly useful for this purpose,
because when constructed using disease relevant expression
profiles they can capture the tissue and cell-type-specific nature
of disease (Nayak et al., 2009; Zhang and Horvath, 2005).
The goal of this study was to use a bone co-expression
network to inform BMD GWAS. We used a co-expression
network constructed from mouse cortical bone expression pro-
files due to the lack of similar (i.e., bone minus marrow)anuary 25, 2017 ª 2016 The Author(s). Published by Elsevier Inc. 1
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ping mouse homologs of human genes located in GWAS regions
onto network modules, we identified an Osteoblast Functional
Module containing 33 genes implicated by GWAS. These genes
are candidates for 30 of the 64 GEFOSII BMD GWAS regions.
Importantly, by characterizing specific network connections,
we were also able to predict how these genes influenced
BMD. As a proof of principle, we determined whether genes
we predicted to be causal at two separate BMD GWAS loci
were involved in the regulation of BMD. We confirmed our pre-
dictions using in vitro and in vivo approaches, and at both loci
the data support the causality of the investigated genes. We
expect this approach will be useful to interrogate GWAS data
for other complex diseases.
RESULTS
Identification of the Osteoblast Functional Module
Defining a List of Genes Implicated by BMD GWAS
An overview of our strategy to inform BMD GWAS is shown in
Figure 1A. We began by generating a list of genes located within
BMD GWAS loci. As a set of loci, we used the 64 independent
associations (p < 5.0 3 108) for FNBMD and/or LSBMD
identified by the GEFOSII GWAS meta-analysis (discovery and
replication n 83,000) (Table S1) (Estrada et al., 2012). We
included all RefSeq genes that were locatedwithin or overlapped
with the region defined by linkage disequilibrium (LD; r2R 0.7) for
each of the 64 lead GWAS SNPs. If a region did not contain or
overlap a gene, we included the genes closest up- and down-
stream. The resulting BMD GWAS Implicated Gene list (BGIG)
contained 167 genes (Table S2). The number of genes per asso-
ciation ranged from 2 to 16, with a mean of 2.8 ± 1.9. The BGIG
was enriched for gene ontology (GO) terms such as ‘‘ossifica-
tion’’ (p = 9.2 3 1011), ‘‘skeletal system development’’ (p =
2.2 3 108), ‘‘bone remodeling’’ (p = 1.8 3 107), and ‘‘osteo-
blast differentiation’’ (p = 6.6 3 107) (full list in Table S3),
suggesting it contained many truly causal BMD GWAS genes.
Identifying BGIG Genes Co-expressed in Bone
BGIG genes were identified based solely on their proximity to
GWAS variants; therefore, only a subset of BGIG genes is ex-
pected to be causal for BMD. We hypothesized that the causal
subset could be identified based on their co-expression in
bone. Thus, to pinpoint potentially causal genes, we mapped
the mouse homologs of BGIG genes (n = 148 of 167) onto a
mouse cortical bone co-expression network. The network was
constructed using cortical bone expression profiles from 96
inbred strains of the Hybrid Mouse Diversity Panel (HMDP)
(Calabrese et al., 2012). The network is unique because samples
profiled were marrow-free cortical bone fragments. As a result,
the expression profiles primarily represented cells of the
osteoblast lineage (osteocytes and mature bone-forming osteo-
blasts) (Bonewald, 2011). Osteocytes and osteoblasts along
with bone-resorbing osteoclasts represent the three key cell
types responsible for bone modeling and remodeling (Seeman,
2009). The network consisted of 10,968 genes partitioned into
21 co-expression modules. Of the 148 BGIG homologs, 97
(66%) were members of at least one network module; a
significant enrichment of genes mapping to the network over
the number expected by chance (odds ratio [OR] = 1.8; Fisher’s2 Cell Systems 4, 1–14, January 25, 2017p = 8.123 106). Of the 21 networkmodules, two (modules 6 and
9) were significantly enriched for BGIG homologs (OR = 3.2,
Fisher’s p = 3.0 3 104 and OR = 4.7, Fisher’s p = 4.0 3 104,
respectively) (Figure 1B). A total of 22 (23%) BGIG homologs
weremembers ofmodules 6 and 9 (n = 14 and n = 8, respectively)
(Table 1).
To determine whether the enrichments for modules 6 and 9
were specific to the BMDGWAS, we identified 18 GWAS studies
for a wide-range of diseases with a similar number (n > 50 and <
70) of genome-wide significant loci and defined gene lists and
calculated enrichments using the same parameters as we
did for the BMD GWAS. Modules 6 and 9 were not significantly
(p % 2.7 3 103) enriched for genes implicated by any of the
other 18 GWAS (Figure S1).
Modules 6 and 9 Contain Functionally Related Genes
We previously observed that modules 6 and 9 shared a number
of similarities (Calabrese et al., 2012). For instance, genes in both
modules are preferentially expressed in bone-forming osteo-
blasts (Calabrese et al., 2012). To more formally evaluate the
relationship between the two modules, we created a network
based on the eigengene of each of the 21 modules (Figure 1C).
In this network, the module 6 and 9 eigengenes clustered
together, and as would be expected their eigengenes were
highly correlated (r = 0.63, p = 3.4 3 1012) (Figure 1D).
We next evaluated shared gene ontology (GO) enrichments
to determine whether the similarity in the behavior meant that
both modules contained functionally related genes. Modules 6
and 9 were nominally enriched (p value <0.001) for 731 and
253 GO terms, respectively. Of these, 189 (74.7% of the total
module 9 terms) terms were enriched (p < 0.001) in both
modules. Furthermore, we observed a positive correlation in
fold enrichments and enrichment significance for shared terms
(Figures 1E and 1F). Most of the ontologies shared between
the modules described cellular components, biological pro-
cesses, and molecular functions pertinent to osteoblasts, such
as ‘‘extracellular matrix’’ (module 6 p = 3.0 3 1026 and module
9 p = 1.5 3 1022), ‘‘ossification’’ (module 6 p = 2.9 3 1014
and module 9 p = 1.0 3 1015), ‘‘bone development’’ (module
6 p = 2.43 1012 and module 9 p = 2.53 106), and ‘‘osteoblast
differentiation’’ (module 6 p = 2.03 107 and module 9 p = 3.53
107) (Figures 1E and 1F).
Identifying Additional Putatively Causal BGIG Genes
Membership within a co-expression module is based on a
particular threshold in connection strength. However, in many
cases a gene just missing this threshold of similarity for a
particular module may still be functionally related to the genes
in that module. Also, genes responsible for orchestrating mod-
ule behavior (e.g., a transcription factor coordinating module
co-expression) are not always members of the module due to
having many weak or moderate correlations with module mem-
bers as opposed to a few strong ones (Calabrese et al., 2012).
Therefore, to more comprehensively identify putative causal
genes in the BGIG, we identified all BGIG genes that were
not members of modules 6 and 9, but whose expression corre-
lated (r R j0.40j, p < 5.0 3 105) with the modules 6 and/or 9
eigengene. To increase specificity, we also required the corre-
lations with the eigengenes of modules 6 and/or 9 be the stron-
gest of the 21 modules. There were 11 genes fitting these
criteria (Table 1).
Figure 1. Identification of the Osteoblast Functional Module
(A) Overview of the approach used to predict genes responsible for BMD GWAS associations.
(B) Enrichment of genes located in BMD GWAS regions in network modules 6 and 9.
(C) Eigengenes for modules 6 and 9 cluster.
(D) Module 6 and 9 eigengenes are highly correlated.
(E and F) (E) Gene ontology fold enrichments and (F) significance are correlated for GO terms shared between modules 6 and 9.
(G) The OFM is a cohesive, highly interconnected functional module. OFM genes with a topological overlap measure (TOM) of 0.05 are connected. A darker-red
color indicates increased number of connections with other OFM genes.
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Based on the data above, we merged the 22 BGIG genes map-
ping tomodules 6 and 9 and the 11 additional BGIG genes corre-lated with the eigengene of either module into what we termed
the osteoblast functional module (OFM). We evaluated connect-
edness in the OFM to ensure it represented a cohesive set ofCell Systems 4, 1–14, January 25, 2017 3
Table 1. OFM Genes
GWAS SNP Chr SNP Position (Mbp) Gene Gene Position (Mbp) Modulea Groupb Novelc Referenced
rs7521902 1 22.164 WNT4 22.143 9 OFM_9 no 25108526, 25108526
rs6426749 1 22.385 WNT4 22.143 9 OFM_9 no 25108526, 25108526
rs17482952 1 68.174 WLS 68.233 9 OFM_9 no 22745162, 22745162
rs12407028 1 68.182 WLS 68.233 9 OFM_9 no 22745162, 22745162
rs479336 1 172.230 DNM3OS 172.145 6 OFM_6 no 18985749, NA
rs4233949 2 54.433 SPTBN1 54.456 6 OFM_6 yes NA
rs17040773 2 111.742 MERTK 111.899 0 OFM_R yes NA
rs1346004 2 165.745 GALNT3 165.794 0 OFM_R no 22912827, 25899975
rs6532023 4 87.853 MEPE 87.821 6 OFM_6 no 12421822, 12421822
rs1366594 5 89.080 MEF2C 88.904 6 OFM_6 no 17336904, 21652706
rs13245690 7 121.145 CPED1 120.989 6 OFM_6 yes NA
rs13245690 7 121.145 WNT16 121.325 6 OFM_6 no 25306234, 25306234
rs3801387 7 121.335 FAM3C 121.396 6 OFM_6 yes NA
rs3801387 7 121.335 WNT16 121.325 6 OFM_6 no 25306234, 25306234
rs2062377 8 118.995 SAMD12 118.622 0 OFM_R yes NA
rs2062377 8 118.995 TNFRSF11B 118.952 9 OFM_9 no 9108485, 9950424
rs7851693 9 130.603 FUBP3 130.580 0 OFM_R yes NA
rs1373004 10 52.668 DKK1 52.314 6 OFM_6 no 16753024, 16753024
rs7071206 10 77.642 KCNMA1 77.638 6 OFM_6 yes NA
rs7071206 10 77.642 DLG5 77.927 9 OFM_9 yes NA
rs7108738 11 15.689 INSC 15.112 9 OFM_9 yes NA
rs7932354 11 46.701 LRP4 46.919 9 OFM_9 no 25733894, 25733894
rs3736228 11 68.434 LRP5 68.313 9 OFM_9 no 11956231, 11956231
rs3736228 11 68.434 PPP6R3 68.461 0 OFM_R yes NA
rs2887571 12 1.529 WNT5B 1.617 6 OFM_6 no 26273529, NA
rs2016266 12 53.334 SP7 53.345 9 OFM_9 no 11792318, 11792318
rs736825 12 54.024 HOXC6 54.017 6 OFM_6 no 1100234, NA
rs1053051 12 106.973 TMEM263 106.956 3 OFM_R yes NA
rs11623869 14 103.417 MARK3 103.385 0 OFM_R yes NA
rs1564981 16 50.952 CYLD 50.742 0 OFM_R no 18382763, NA
rs1566045 16 50.988 CYLD 50.742 0 OFM_R no 18382763, NA
rs4790881 17 2.166 HIC1 2.055 0 OFM_R yes NA
rs4790881 17 2.166 SMG6 2.304 0 OFM_R yes NA
rs4792909 17 43.721 MEOX1 43.662 6 OFM_6 no 12538525, NA
rs4792909 17 43.721 SOST 43.759 6 OFM_6 no 11181578, 15024046
rs227584 17 44.148 HDAC5 44.124 1 OFM_R no 25271055, 19920351
rs3790160 20 10.659 BTBD3 11.891 6 OFM_6 yes NA
aCoexpression network module from Calabrese et al. (2012).
bOFM gene group, OFM_6 = member of module 6, OFM_9 = member of module 9, and OFM_R = not a member of module 6 or 9, but expression was
highly correlated with the module 6 or 9 eigengene.
cWhether or not a gene is novel with respect to the regulation of BMD and/or osteoblast activity.
dReference PMID number demonstrating a known gene is involved in BMD (first #) and osteoblast activity (second #).
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tween genes was r = 0.29. This represented a significant (p <
0.001) enrichment over what would be expected by chance
(Figure S2), indicating that as a group, OFM genes were co-ex-
pressed and highly interconnected (Figure 1G).
Of the 33 OFM genes, 18 (55%) have been shown to regulate
BMD in humans or mice and 13 of the 18 (72%) have been
directly implicated in the function of osteoblast-lineage cells4 Cell Systems 4, 1–14, January 25, 2017(Table 1). This includes genes such as LDL receptor related pro-
tein 5 (LRP5), Sp7 transcription factor (SP7; aka osterix), tumor
necrosis factor receptor superfamily member 11b (TNFRSF11B;
aka osteoprotegerin), and sclerostin (SOST), which are among
the best-known and most well-characterized genes involved in
the regulation of osteoblast-lineage cells and BMD (Balemans
et al., 2001; Brunkow et al., 2001; Gong et al., 2001; Little
et al., 2002; Nakashima et al., 2002; Simonet et al., 1997). To
Figure 2. OFM Genes Are in Close Proximity to Lead BMD GWAS SNPs
(A) OFM (pink) and non-OFM genes (green) were plotted based on their distance from the lead GWAS SNP in each of 30 OFM loci. Loess lines indicate that OFM
genes tend to be closer to lead SNPs across most associations.
(B) The percentage of OFM GWAS loci in which OFM or non-OFM (NOFM) genes are the closest to the lead SNP.
(C) The percentage of OFM or NOFM genes closest to the lead SNP at any association.
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expected by chance, we searched whole-body BMD data on
1928 mouse mutants (selected at random with respect to known
involvement in BMD) from the International Mouse Phenotyping
Consortium (IMPC) (Brown and Moore, 2012a, 2012b). In the
IMPC, 6.3% (122 of 1928) of mouse knockouts exhibited a
BMDphenotype compared to 55% recovery of known regulators
of BMD in the OFM (OR = 8.6, Fisher’s p = 9.63 1010), confirm-
ing that with respect to the regulation of BMD, the OFM is not a
random gene set.
OFM Genes Have Characteristics of a Causal Gene Set
Proximity to Lead BMD GWAS SNPs
We next set out to generate additional evidence that OFM genes
are likely to be causal. It has recently been shown that for a given
GWAS locus the gene nearest to the lead SNP is not always
causal (Claussnitzer et al., 2015; Smemo et al., 2014). However,
we would expect across multiple GWAS loci that causal genes
would tend to be located closer to lead SNPs than non-causal
genes, as shown in studies mapping local expression quantita-
tive trait locus (eQTL) (Veyrieras et al., 2008). Therefore, for the
30 GWAS loci that contain at least one OFM gene (referred to
as OFM loci), we calculated the distance between the lead
GWAS SNP and the distance to the transcription start site
(TSS) for each gene in the locus. When plotted starting from the
locus with the shortest distance from lead SNP to nearest TSS
to the locus with the longest distance between lead SNP and
the nearest TSS there was a clear trend for OFM genes to be
closer to lead SNPs than non-OFM genes (Figure 2A). In fact,OFM genes were the closest to the lead SNP at 21 (70.0%) of
the 30OFM loci (OR=2.3, Fisher’s p=0.07) (Figure 2B). Addition-
ally, of the 33 OFM genes in OFM loci, 26 (76%) were the closest
gene in at least one association, whereas only 8 (20%) of the 40
non-OFM genes in OFM loci were the closest to at least one lead
GWAS SNP (OR = 3.9, Fisher’s p = 3.2 3 103) (Figure 2C).
OFM SNPs Overlap Regulatory Elements in Osteoblasts
Of the 30 OFM loci, only three harbored lead SNP proxies (r2 >
0.7) that were nonsynonymous variants, suggesting that most
of the OFM loci influence BMD by altering gene regulation.
Thus, if OFM genes are truly causal and their mechanism of ac-
tion is to influence osteoblast activity, we would expect that the
associations would influence BMD by altering gene expression
in osteoblasts. To determine whether this is the case, we as-
sessed the overlap between lead SNPs in OFM loci (n = 30)
and all non-OFM loci (n = 34) and histone modifications marking
regulatory elements in primary human osteoblasts (ENCODE
Project Consortium et al., 2012; Kundaje et al., 2015). We
observed a higher level of overlap with six histone modifications
that are marks of active transcription for OFM lead SNPs as
compared to non-OFM lead SNPs (Figure 3A). The opposite
was seen for two repressive histone modifications (Figure 3A).
This was most prominent for H3K27ac and H3K4me2, which
showed significant increases in overlap with OFM SNPs as
compared to non-OFM SNPs (Fisher’s p = 0.02). H3K27ac and
H3K4me2 binding is associated with enhancer elements and
regions of transcription factor binding, respectively (ENCODE
Project Consortium et al., 2012). For both modifications, as
well as H3K4me3 (associated with promoter elements), weCell Systems 4, 1–14, January 25, 2017 5
Figure 3. Lead SNPs in OFM Loci Overlap Active Regulatory Elements Specifically in Primary Human Osteoblasts
(A) Overlap between lead GWAS SNPs and histone modifications at OFM and non-OFM (NOFM) loci in primary human osteoblasts and 1000 randomly selected
SNP sets.
(B) ChromHMM state segmentations in osteoblasts overlaps with lead GWAS SNPs in OFM and NOFM loci.
(C) Expression of OFMgenes andNOFMgenes inOFM loci andNOFMgenes in NOFM loci in bone and primary human osteoblast samples. Data are presented as
mean ± SEM.
(D) Difference in percentage OFM overlap versus percentage NOFM overlap (from A) plotted against percentage OFM overlap in the 97 cell lines and tissues for
the H3K27ac modification.
(E) Same as in (D) for H3K4me2.
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pected by chance (p < 0.001) by comparison with 1000 sets of 30
randomly selected SNPs, matched with OFM SNPs on minor
allele frequency and distance from the nearest TSS (Figure 3A).
OFM SNPs were also more likely to lie in locations annotated
as regulatory elements using ChromHMM genome segmenta-
tions in osteoblasts (Ernst and Kellis, 2012) (Figure 3B). We
also observed that OFM genes were on average 2-fold more
highly expressed in either osteoblasts or bone than non-OFM
genes in either OFM (p = 0.02) or non-OFM loci (p = 9 3 103)
(Figure 3C). Similar overlap was observed using lead SNPs and
proxies at both r2 = 1.0 and r2 = 0.8 (data not shown).
To determine whether the increase in overlap with histone
modifications was specific to osteoblasts, we focused on data
for H3K27ac and H3K4me2 in a large number of cell types
from the NIH Epigenomics Roadmap project (Kundaje et al.,
2015). We focused on H3K27ac and H3K4me2 because they
demonstrated the most significant enrichments with lead
OFM SNPs in primary human osteoblasts (Figure 3A), and, as6 Cell Systems 4, 1–14, January 25, 2017mentioned above, they are known to mark enhancers (ENCODE
Project Consortium et al., 2012). For both modifications, we
observed that osteoblasts were among the cell types with the
largest difference in overlap between the OFM and non-OFM
SNP groups as well as having the highest level of OFM overlap
(upper right quadrant) (Figure 3D). Moreover, the cell types that
grouped with osteoblasts were highly related cell types such
as chondrocytes, fibroblasts, and mesenchymal stem cells
(MSCs; osteoblasts are derived from MSCs). Similarly for
H3K4me2, myotubes and myoblasts grouped with osteoblasts
in the upper right quadrant, both of which are derived from
MSCs (Figure 3E). Together, these data are consistent with
OFM loci influencing BMD by altering gene expression in osteo-
blasts, which strengthens our prediction that OFM genes in
these loci are more likely to be causal than non-OFM genes.
Using the OFM to Inform GWAS
Based on the data above, OFM genes are strong candidates to
underlie their respective associations. To use the OFM to inform
Figure 4. SPTBN1 Is a Strong Candidate
Causal Gene for a GWAS Association on
Chromosome 2p16.2
(A) GEFOSII GWAS discovery phase p values for
LSBMD in the GWAS locus on chromosome
2p16.2. Of the two genes, C2orf73 and SPTBN1,
in the locus Sptbn1 was a member of the OFM.
(B) Residuals of whole-body BMD adjusted for
batch and body weight by genotype and sex
for mice homozygous for a gene-trap allele of
4930505A04Rik, the mouse homolog of C2orf73.
(C) Residuals of whole-body BMD adjusted for
batch and body weight by genotype and sex for
mice heterozygous for a Sptbn1 gene-trap allele.
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based on whether the OFM gene(s) in the locus was known, pre-
viously demonstrated to regulate BMD in humans or mice, or
novel, not previously shown to regulate BMD. The three groups
included loci containing: (1) only known OFM genes, (2) known
and novel OFM genes, and (3) only novel OFM genes (Table 1).
A total of 21 of the 30 (70%) OFM loci fell into one of the first
two groups. We expect that many of the known OFM genes
to be causal at their respective association. The remaining nine
associations harbored only novel OFM genes. These nine loci
are high priority for functional follow-up given their potential to
provide new insight on the regulation of BMD. As a proof of
principle, we selected two of the nine (chromosomes 2p16.2
and 14q32.32) loci for experimental interrogation.
SPTBN1 Is a Candidate Causal Gene for the BMD GWAS
Locus on Chromosome 2p16.2
Chromosome 2p16.2 contained SNPs associated with LSBMD
(discovery p = 5.0 3 1012 and discovery + replication p =
2.25 3 1018) (Figure 4A). This locus was also one of six in
the GEFOSII meta-analysis that were associated with osteopo-
rotic fracture (p = 2.6 3 108) (Estrada et al., 2012). The lead
SNP, rs4233949, was located within an intergenic region 23
kilo-base pairs (Kbp) from the spectrin, beta, non-erythrocytic
1 (SPTBN1) TSS and 100 Kbp from the TSS for chromosome
2 open reading frame 73 (C2orf73; 4930505A04Rik is its homo-
log in the mouse). C2orf73 encodes for a protein of unknown
function and SPTBN1 encodes for beta spectrin, a molecular
scaffolding protein that links the actin cytoskeleton to the
plasma membrane (Viel and Branton, 1996). C2orf73 and
SPTBN1 represented the locus in the BGIG list and SPTBN1
was a member of the OFM (4930505A04Rik was not part of
the bone network) (Table 1). Consistent with its known function,
the 50 genes most strongly connected to Sptbn1 in the bone
network included genes encoding extracellular matrix (p =
2.2 3 107) proteins and proteins involved in alpha-actinin
binding (p = 1.6 3 105), focal adhesion (p = 0.001), and cell
adhesion (p = 0.001).Based on its membership in the OFM,
we predicted that SPTBN1 was causal.
To test this prediction, we first evaluated
the broad tissue expression profiles for
both genes in mice. The expression of
4930505A04Rik was restricted to testis
(Figure S3). In contrast, Sptbn1 wasbroadly expressed in many tissues and cell types, including
high expression in osteoblasts (Figure S3). The IMPC (Brown
and Moore, 2012a, 2012b) had collected BMD data on
knockouts for both genes. At 14 weeks of age, mice of both
sexes homozygous for a gene-trap allele of 4930505A04Rik
(4930505A04Riktm1b(KOMP)Wtsi; hereafter referred to as
4930505A04Rik/) displayed no difference in BMD relative to
controls (Figure 4B). However, male mice heterozygous for a
gene-trap allele of Sptbn1 (Sptbn1tm1a(EUCOMM)Wtsi; hereafter
referred to as Sptbn1+/) had increased whole-body BMD and
female Sptbn1+/mice had decreased whole-body BMD relative
to controls (genotype p = 0.0014 and sex interaction p = 0.002)
(Figure 4C). These data are consistent with the prediction that
SPTBN1 is involved in the regulation of BMD and is potentially
responsible for the 2p16.2 BMD GWAS locus.
Mark3 Is a Causal Gene for the BMD GWAS Locus on
Chromosome 14q32.32
As further proof of principle, we performed a more detailed
investigation of the BMD GWAS locus on chromosome
14q32.32. We selected this locus because it contained multiple
genes, one of which was a non-OFM gene known to regulate
BMD (brain-type creatine kinase (CKB)); thus, we reasoned it
would provide a rigorous validation of our approach. The locus
was associated with both FNBMD (discovery p = 1.3 3 106
and discovery + replication p = 5.23 10–16) and LSBMD (discov-
ery p = 7.53 104 and discovery + replication p = 5.13 10–11) in
GEFOSII (Estrada et al., 2012) (Figure 5A). The lead SNP,
rs11623869, was located in the second intron of the MAP/micro-
tubule affinity-regulating kinase 3 (MARK3) gene; however,
rs11623869 proxy SNPs (r2 > 0.7) spanned a 157-Kbp interval
also containing CKB and tRNA methyltransferase 61 homolog
A (TRMT61A). Of the three, CKB has been demonstrated to
play a role in the activity of bone-resorbing osteoclasts and
Ckb-deficient mice are protected against bone loss induced by
ovariectomy and inflammatory challenges (Chang et al., 2008).
TRMT61A is a tRNA methyltransferase (Ozanick et al., 2005),
and MARK3 is a member of the AMPK family of kinases (BrightCell Systems 4, 1–14, January 25, 2017 7
Figure 5. MARK3 Is a Strong Candidate Causal Gene for a GWAS Association on Chromosome 14q32.32
(A) GEFOSII GWAS discovery phase p values for FNBMD in the locus on chromosome 14q32.32. Of the three genes,MARK3,CKB, and TRMT61A, located in the
association Mark3 was a member of the OFM.
(B) In the HMDP, Mark3 expression is negatively correlated with Sp7 (osterix), a key transcription factor required for osteoblast differentiation.
(C) Knockdown of Mark3 in primary calvarial osteoblasts using two siRNAs (M1 and M2) compared to a scrambled control (SC).
(D) Images of cultures stained with alizarin red 10 days after transfection with SC, M1, or M2.
(E and F) Quantification of (E) alizarin red staining and (F) nodule counts 10 days after transfection with SC, M1, or M2.
(G) In the HMDP, Mark3 expression is negatively correlated with femoral BMD.
(H) Mark3 transcript levels in embryos are reduced in mice harboring the tm1a gene-trap allele.
(I and J) (I) Spine and (J) femur BMD in male heterozygous gene-trap mice (+/) and wild-type littermates (+/+) at 12 and 16 weeks of age.
(K–M) (K) Cortical bone fraction (BA/TA), (L) cortical thickness (Ct.Th), and (M) tissuemineral density (TMD) in gene-trap mice (/) and wild-type littermates (+/+).
(N–Q) (N) Trabecular bone fraction (BV/TV), (O) trabecular number (Tb.N), (P) trabecular thickness (Tb.Th), and (Q) trabecular separation (Tb.Sp) in male
homozygous gene-trap (/) and wild-type littermates (+/+) at 12 weeks of age.
(R–U) (R) Biomechanical strength (F), (S) stiffness (S), (T) work, and (U) post-yield deflection in gene-trap mice (/) and wild-type littermates (+/+). Plotted values
in I-U are lsmeans ± SEM, *p < 0.05.
In (C), (E), (F), and (H)–(U), data are presented as mean ± SEM.
Please cite this article in press as: Calabrese et al., Integrating GWAS and Co-expression Network Data Identifies Bone Mineral Density Genes
SPTBN1 and MARK3 and an Osteoblast Functional Module, Cell Systems (2016), http://dx.doi.org/10.1016/j.cels.2016.10.014et al., 2009). TRMT61A andMARK3 have not been implicated in
the regulation of BMD.
CKBwas a strong candidate for this locus based on its known
role in the regulation of BMD; however, based on its membership
in the OFM we predicted that MARK3 was at least partially
responsible for the effects of the locus. To determine how
MARK3may influence BMD, we went back to the OFM and eval-
uated the relationship between Mark3 and other OFM genes.8 Cell Systems 4, 1–14, January 25, 2017Mark3 expression was negatively correlated with all other OFM
genes. It was most strongly negatively correlated with the
expression of Sp7, a key transcription factor required for osteo-
blast differentiation (Figure 5B), suggesting that Mark3 was a
negative regulator of osteoblast differentiation.
To test this hypothesis, we first confirmed thatMark3 was ex-
pressed in osteoblasts. Across 96 different mouse tissues and
cell types, we observed thatMark3 expression was ubiquitously
Please cite this article in press as: Calabrese et al., Integrating GWAS and Co-expression Network Data Identifies Bone Mineral Density Genes
SPTBN1 and MARK3 and an Osteoblast Functional Module, Cell Systems (2016), http://dx.doi.org/10.1016/j.cels.2016.10.014expressed, with strong expression in osteoblasts (Figure S4).
In primary calvarial osteoblasts, Mark3 expression started high
and decreased as a function of differentiation (Figure S4).
We also observed its expression in 3T3-E1 cells, a mouse oste-
oblast cell line, by immunofluorescence and its expression in
osteoblast-lineage cells in bone was confirmed by immunohisto-
chemistry (Figure S4).
We then used two small interfering RNAs (siRNAs) (M1 and
M2) to knockdown the expression of Mark3 in mouse primary
calvarial osteoblasts. At 48 hr post-transfection in undifferenti-
ated cells, Mark3 transcript levels were reduced to 21% and
32% of the scrambled control in M1 and M2 transfected cells,
respectively (p < 0.05) (Figure 5C). Primary osteoblasts can be
induced to mineralize in vitro, which is a marker of the rate of dif-
ferentiation/maturation. At 10 days post-differentiation, Mark3
knockdown resulted in dose-dependent increases in the forma-
tion of mineralized nodules (Figure 5D) as measured by alizarin
red staining (which stains mineralized nodules, p < 0.05, Fig-
ure 5E) and the number of nodules formed (p < 0.05, Figure 5F).
We next measured the correlation between Mark3, Ckb, and
Trmt61a expression and femoral BMD in the HMDP (population
used to generate the bone network). Of the three,Mark3was the
only gene correlated with femoral BMD (r = 0.25, p = 0.036)
(Figure 5G). These data, together with the in vitro experiments,
suggested that Mark3 was a negative regulator of BMD.
To test this prediction, we generated mice carrying a Mark3
gene trap allele (Mark3tm1a(KOMP)Mbp; hereafter referred to as
Mark3/). The gene trap allele decreased Mark3 levels by
47%and 85% inMark3+/ andMark3/malemice, respectively
(Figure 5H). We generated two cohorts of male mice. In the first,
we measured BMD in Mark3+/ and Mark3+/+ male mice at 12
and 16 weeks of age. A decrease in Mark3 levels had no effect
on BMD at the spine at either age (Figure 5I). However, at both
time points we observed significantly (p < 0.05) increased
femoral BMD inMark3+/mice compared toMark3+/+ littermates
(Figure 5J). This is consistent with the stronger association
between rs11623869 and FNBMD, as compared to LSBMD, in
GEFOSII (Estrada et al., 2012).
We used mCT in the second cohort to evaluate the effect of a
decrease in Mark3 on cortical and trabecular microarchitecture
of the femur in 12-week-old male Mark3/ and Mark3+/+ mice.
These data revealed that the decrease in Mark3 levels primarily
increased cortical bone, with significant (p < 0.05) increases in
cortical bone area fraction (BA/TA), cortical thickness (Ct.Th),
and tissue mineral density (TMD) in male Mark3/ compared
to Mark3+/+ littermates (Figures 5K–5M). Trabecular bone vol-
ume fraction (BV/TV), trabecular number (Tb.N) and trabecular
separation (Tb.Sp) were not altered in the distal femur of
Mark3/ mice (p > 0.05), but we did observe a significant (p <
0.05) increase in trabecular thickness (Tb.Th) (Figures 5N–5Q).
The increase in cortical bone mass was associated with a
suggestive increase in bone strength (p = 0.10) (Figure 5R) and
a significant (p < 0.05) increase in femoral stiffness in male
Mark3/ mice (Figure 5S). No differences were observed in
Work (ameasure of toughness) (Figure 5T) and post-yield deflec-
tion (a measure of ductility) (Figure 5U).
During the course of our study, eQTL results from the Gene
Tissue Expression (GTEx) project became available, so we
went back and further investigated the associated region. Ofthe 117 SNP proxies (r2 > 0.7) for rs11623869, only two were
coding and they were synonymous variants in CKB, suggesting
that the variant(s) underlying the association with BMD is regula-
tory. Many of these proxies were located in putative regulatory
regions (marked by H3K4me2, H3H27ac, etc.) in human osteo-
blasts (Figure 6A) and other cell types (data not shown). We
queried GTEx to determine whether any of three genes in the re-
gion were regulated by the same variants associated with BMD.
SNPs in the region were significantly (p < 1.03 105) associated
with the expression of MARK3 in nine different tissues, CKB in
eight different tissues, and TRMT61A in seven different tissues
(Figures 6B–6D). We used a Bayesian colocalization test to eval-
uatewhether the genetic data best fit amodel in which the eQTLs
(most significant for each gene) and BMD associations were due
to a single shared pleiotropic variant (model 4) or two indepen-
dent variants (model 3). For MARK3 the strongest eQTL was in
thyroid tissue and the posterior probability for the model of a
single shared variant (PP4) underlying the eQTL and BMD asso-
ciation was 97.4% compared to the model of two independent
variants (PP3 = 2.5%) (Figure 6B). The two independent variant
model was favored for the CKB eQTL in skin tissue (PP3 =
68.7% versus PP4 = 26.1%) (Figure 6C) and the single shared
variant model was favored for the TRMT61A eQTL in aorta tissue
(PP4 = 93.5% versus PP3 = 5.2%) (Figure 6D). Importantly, as
seen in mice, the ‘‘T’’ allele of rs11623869 was associated with
increased (p < 1.0 3 107) MARK3 levels, across many tissues,
and decreased FNBMD (Figure 6E). These data indicate that
lower levels ofMARK3 in both humans and mice are associated
with increased BMD. Though they do not exclude the involve-
ment of other genes in the region, these data are consistent
with the hypothesis that MARK3 is a causal BMD GWAS gene
and at least partially responsible for the effects of the chromo-
some 14q32.32 association.
DISCUSSION
Our goal was to use a network-driven approach to predict puta-
tive causal genes for 64 genomic regions robustly associated
with BMD. Using a disease-relevant co-expression network to
inform GWAS, we were able to identify putative causal genes
for 30 of 64 BMD GWAS loci. Based on the function of known
genes within the OFM, and modules 6 and 9 as a whole, we
were also able to infer that OFMgenes impacted BMDby altering
the activity of bone-forming osteoblasts. Our predictions repre-
sent a key first step in systematically interrogating each locus
and generating a much deeper understanding of the genes and
cellular processes that regulate BMD in humans.
We identified two network modules (6 and 9) that contained
more genes implicated by GWAS than would be expected by
chance. From prior work, we know that each of the 21 network
modules are enriched for genes involved in particular biological
processes. Modules 6 and 9 were enriched for processes spe-
cific to osteoblasts, such as ‘‘osteoblast differentiation’’ and
‘‘osteoblast proliferation’’ (Calabrese et al., 2012). The bone
co-expression network was generated using transcriptomic pro-
files of marrow-free cortical bone fragments. Bone fragments
primarily (>90%) consist of cells of the osteoblast-lineage (mainly
osteocytes) (Bonewald, 2011). This likely underlies the reason
that a similar ‘‘osteoclast’’ functional module was not found,Cell Systems 4, 1–14, January 25, 2017 9
Figure 6. MARK3 Expression in Multiple Tissues Is Regulated by the Same Variants Associated with BMD
(A) H3K4me2 and H3K27ac modifications in primary human osteoblasts across the chromosome 14q32.32 association.
(B–D) Local eQTL influencing (B)MARK3 expression in thyroid tissue, (C)CKB expression skeletal muscle, and (D) TRMT61A expression in aorta. In (B)–(D), PP4 is
the posterior probability that the eQTL and BMD associations share a single common variant and PP3 is the posterior probability for the region harboring two
independent variants, each affecting either gene expression or BMD.
(E) Effect of the ‘‘T’’ allele of rs11623869 (lead GWAS SNP at the chromosome 14q32.32 locus) on BMD (in red) and the expression ofMARK3 in multiple tissues.
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by the osteoblast and resorption by the osteoclast (Boyle et al.,
2003), and several genes implicated by GWAS (particularly at the
34 non-OFM loci), such as TNFSF11 (Yasuda et al., 1998) and
PLEKHM1 (Van Wesenbeeck et al., 2007), play key roles in oste-
oclast biology. In fact, in our previous characterization of the co-
expression network, none of the 21 modules demonstrated a
strong ‘‘osteoclast’’ signature, likely due to the low numbers of
osteoclasts that would have been included in the expression
profiles used to construct the network (Calabrese et al., 2012).
One might expect that an osteoclast-specific network would
yield a functional module potentially informative for the non-
OFM GWAS loci.
For our analysis, we used a mouse bone co-expression
network. Using a mouse network had its limitations, such as
missing genes due to the lack of homologs, and we could not
consider non-coding RNAs as potentially causal genes. How-
ever, there were advantages to using this network. For example,
the network had been well characterized (Calabrese et al., 2012;
Farber et al., 2011; Mesner et al., 2014), and it was generated
from cortical bone samples free of marrow. This last point is10 Cell Systems 4, 1–14, January 25, 2017important since the profiles primarily represented bone cells,
instead of marrow cells, and similar data have not been gener-
ated from a large number of human samples. We do expect,
however, that networks derived from human bone transcrip-
tomic data would lead to more informative networks for the
purpose of informing BMD GWAS.
We predicted that the OFM was highly enriched for truly
causal genes based on the following observations: (1) OFM
genes were located in BMD GWAS loci, (2) OFM genes were
co-expressed in bone, (3) 55% of OFM genes were known reg-
ulators of BMD, (4) OFM genes were closer to lead GWAS
SNPs than non-OFM genes, and (5) lead SNPs in OFM loci
were located within osteoblast-specific regulatory elements.
The overlap of lead OFM SNPs and osteoblast regulatory ele-
ments suggest that OFM loci impact BMD by altering the target
genes in osteoblasts and the OFM provides a list of potential
targets. These data strengthen the assertion that OFM genes
are responsible for the effects of OFM loci. Our results also
suggest that a significant fraction of the genetic signal for
BMD identified to date influences BMD by altering the activity
of osteoblast-lineage cells.
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SPTBN1 and MARK3 and an Osteoblast Functional Module, Cell Systems (2016), http://dx.doi.org/10.1016/j.cels.2016.10.014We observed a number of BMD GWAS loci that harbored
multiple OFM genes. There are at least two possible explana-
tions for this observation. First, it is highly likely that not all
OFM genes are responsible for BMD GWAS signals. Though
such genes may be involved in osteoblast activity due to their
membership in the OFM, the localization of some OFM genes
inGWAS regions is expected to be coincidental. A second expla-
nation is that at a subset of BMD GWAS loci there are multiple
functional genes. An example is the chromosome 7q31.31 re-
gion, which contained two independent associations in GEFOSII
and three OFM genes;WNT16, FAM3C, and CPED1. This region
appears to be quite genetically complex and there is evidence
from other GWASs that it contains more than just the two asso-
ciations identified by GEFOSII (Chesi et al., 2015; Cho et al.,
2009; Estrada et al., 2012; Kemp et al., 2014; Medina-Go´mez
et al., 2012; Moayyeri et al., 2014; Zhang et al., 2012; 2013a).
As a result, it is possible that all three OFM genes located in
the 7q31.31 region are responsible for independent genetic
associations with BMD.
The BMD GWAS locus on chromosome 2p16.2 harbors var-
iants spanning an 10-Kbp intergenic region flanked by two
genes, C2orf73 and SPTBN1. Sptbn1 was a member of the
OFM, and, of the two genes, BMD was altered in mice with
perturbed Sptbn1 expression. SPTBN1 is a molecular scaf-
folding protein that links the actin cytoskeleton to the plasma
membrane (Zhang et al., 2013b). Through this role, it has been
implicated in the regulation of cell shape, adhesion, and trans-
forming growth factor b (TGF-b) signaling (Zhang et al.,
2013b). It was most strongly connected to genes involved in
alpha-actinin binding and cell adhesion in the bone co-expres-
sion network, suggesting that it plays the same role in bone. In
mice, the effect of Sptbn1 perturbation was sexually dimor-
phic; however, the chromosome 2p16.2 locus affected BMD
equally in both sexes. In mice, sexually dimporphic effects
of genetic perturbations is common (as an example, Mesner
et al., 2014). In humans, however, there is little evidence that
genetic effects on BMD differ between sexes (Liu et al.,
2012a). There are many potential explanations as to why
global knockouts in mice show sexually dimorphic effects on
bone. Most importantly though, the data presented link
Sptbn1 to the regulation of BMD. Although further work is
needed to determine how the chromosome 2p16.2 locus influ-
ences BMD, our results suggest that SPTBN1 plays a role in
the 2p16.2 association.
MARK3 is one of four mammalian homologs of the
C. elegans partitioning defective 1 (par1) kinase that regulates
cell polarity (Drewes et al., 1998). MARK3 is a member of the
AMP-kinase (AMPK) family, which has been found to partici-
pate in diverse cellular functions (Bright et al., 2009). Mice
deficient in Mark3 have been shown to be resistant to high-
fat-diet-induced obesity, hepatic steatosis, and diabetes (Len-
nerz et al., 2010). We demonstrated that in both humans and
mice, MARK3 transcript levels are negatively correlated with
BMD. Using GTEx data, we observed that MARK3 was regu-
lated by the same eQTL in nearly every tissue. Even though
bone tissue and bone cells are not included in GTEx, it is likely
that the pan-tissue local eQTL we identified is also operative in
bone cells. In the mouse, Mark3 expression started out high in
primary osteoblasts and significantly decreased as differentia-tion progressed. Furthermore, its expression was inversely
correlated with key genes involved in osteoblast differentia-
tion. These data suggest that Mark3 may act as a ‘‘brake’’
for osteoblast differentiation and its decrease early in differen-
tiation may remove this brake enabling differentiation to prog-
ress. Altogether, our results provide strong evidence that
MARK3 is responsible for the effects of the BMD GWAS locus
on chromosome 14q32.32.
In summary, through the integration of GWAS data and a bone
co-expression network, we provide predictions of potential
causal genes at 30 BMD GWAS loci and use this information to
identify causal genes for two GWAS loci. Based on our results,
we believe that significant insight into complex disease etiology
can be gained using networks to inform GWAS.
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Antibodies
Rabbit Anti-MARK3 GeneTex GTX111538 MARK3 polyclonal antibody;
RRID: AB_11163524
Chemicals, Peptides, and Recombinant Proteins
Alizarin Red S Sigma (cat. A5533) Alizarin Red
Deposited Data
Mouse: RNA-seq data from primary
calvarial osteoblasts
NCBI GEO GEO: GSE54461
Mouse: Microarray data from primary
calvarial osteoblasts
BioGPS (http://biogps.org) Dataset: GeneAtlas MOE430, gcrma
Humans: Histone modification data and
ChromHMM genome segmentations from
primary osteoblasts and other cell lines/
tissues
Epigenomics Roadmap (http://www.
roadmapepigenomics.org/)
N/A
Human: EQTL from multiple human tissue GTEx (http://gtexportal.org/home/) N/A
Mouse: BMD data on knockout strains from
the International Mouse Phenotyping
Consortium (IMPC)
IMPC webportal (http://www.
mousephenotype.org)
Data for 4930505A04Rik and Sptbn1
knockouts
Human: Microarray data from human bone
biopsies
Reppe et al., 2010 and EBI ArrayExpress
(https://www.ebi.ac.uk/arrayexpress/)
E-MEXP-1618
Human: SNP data NCBI dbSNP dbSNP142
Experimental Models: Cell Lines
Mouse: MC3T3 pre-osteoblasts ATCC MC3T3 clone 4
Mouse: primary calvarial osteoblasts This paper Primary calvarial ostoeblasts
Experimental Models: Organisms/Strains
Mouse: B6 Albino mice Charles River B6N-Tyrc-Brd/BrdCrCrl
Mouse: C57BL6/J mice Jackson Laboratory (Stock #000664) C57BL6/J
Mouse: Mice possessing a Mark3 gene
trap allele
This paper Mark3tm1a(KOMP)Mbp
Sequence-Based Reagents
See Table S1 for all primer sequences This paper N/A
Software and Algorithms
PhenStat R package Kurbatova et al., 2015 N/A
lsmeans R package Lenth, 2016 N/A
ImageJ Schneider et al., 2012 N/A
Plink v1.9 Chang et al., 2015 N/A
topGO R package Alexa and Rahnenfuhrer, 2010 N/A
coloc R Package Giambartolomei et al., 2014 N/A
Adobe Photoshop CS4 Adobe Systems (San Jose, CA) N/ACONTACT FOR REAGENT AND RESOURCE SHARING
As Lead Contact, Charles R. Farber is responsible for all reagent and resource requests. Please contact Charles R. Farber at crf2s@
virginia.edu with requests and inquiries.Cell Systems 4, 1–14.e1–e4, January 25, 2017 e1
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Generation and characterization of Mark3 gene trap mice
The study was carried out in strict accordance with NIH’s Guide for the Care and Use of Laboratory Animals. Additionally, the Uni-
versity of Virginia Institutional Animal Care and Use Committee approved all animal procedures. Mark3 gene trap mice were gener-
ated using targeted embryonic stem cell (JM8A1.N3) clones heterozygous for theMark3tm1a(KOMP)Mbp gene trap allele obtained from
the International Knockout Mouse Project (KOMP; https://www.komp.org). Two (H02 and C06) KOMP ES clones were karyotyped
and injected using a XYClone Laser (Hamilton Thorne, Beverly, MA) into B6N-Tyrc-Brd/BrdCrCrl (Charles River,
Wilmington, MA) 8-cell stage embryos to create chimeric mice. Resultant chimeras were bred to B6N-Tyrc-Brd/BrdCrCrl mice to
obtain germline transmission of theMark3 gene trap allele. Confirmation of transmission in resultant black or brown pups was deter-
mined by PCR using the following two sets of primer pairs: Common-lox-P-F/Mark3-30R and Mark3-50 F/Common-en2-30R (Table
S4). The first and second primer sets resulted in amplicons of 156 bp and 373 bp, respectively, both denoting the presence of the
gene-trap allele. Albino littermates served as negative controls.
Mice heterozygous for the Mark3tm1a(KOMP)Mbp gene-trap allele were intercrossed to generate two cohorts of experimental mice.
PCR was used to genotype experimental mice using primers Mark 3-172-50 and Mark3-30R (Table S4), which resulted in a 238 bp
amplicon from the gene-trap allele and 204 bp amplicon from the wild-type allele. BMDwasmeasured in the first experimental cohort
using DEXA (described below). At weaning, F2micewere randomly allocated to a cage irrespective of genotype.Micewere housed in
Thoren (Thoren Caging Systems, Hazelton, PA) ventilated racks and provided irradiated Teklad diet (Envigo, Huntingdon, UK). Mice
from the second cohort were euthanized and dissected femurs were subjected to mCT and biomechanical testing (described below).
For all procedures the experimenter was blinded to genotype.
Osteoblast cell cultures
MC3T3-E1 clone 4 (MC4) cells were obtained from the American Type Culture Collection (Manassas, VA). These cells were main-
tained in aMEM media (Cellgro, Herndo, VA), supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), penicillin (50 IU/
ml) and streptomycin (50 mg/ml).
Primary calvarial osteoblasts were isolated from 3-9 day old C57BL6/J (Jackson Laboratory, Stock #000664) neonates using
sequential Collagenase P digestions. Cells were plated into 6 well plates at 300,000 cells in 2ml sterile plating media (DMEM,
10% heat-inactivated FBS, 100 U/ml penicillin, 100 mg/ml streptomycin) per well. After 24 hr, confluent cells were washed 1x with
DPBS (GIBCO) and placed in sterile differentiation media (MEM alpha, 10% heat inactivated FBS, 100 U/ml penicillin, 100 mg/ml
streptomycin, 50 mg/ml ascorbic acid, 4 mM B-glycerophosphate). Every 48 hr thereafter cells were washed one time with DPBS
(GIBCO) and differentiation media was replaced until cells were collected for analysis at day 10.
METHODS DETAILS
Mark3 immunohistochemistry
Femurs were fixed in 10% neutral buffered formalin (Fisher Scientific) and decalcified with 4% EDTA for 15 days, dehydrated and
cleared on a tissue processor and embedded in paraffin. Five-micron sections were deparaffinized in xylene followed by increasing
grades of ethanol and rehydrated on slides. Antigen retrieval was accomplished by placing the slides in Coplin jars in 60C citrate
buffer (pH 6) andmaintained at 60C in a water bath for 20min. Endogenous peroxidase was quenched using 3% hydrogen peroxide
and non-specific staining was blocked using 0.1%BSA and 5% normal goat serum in Tris buffered saline. Sections were treated with
rabbit anti-MARK3 polyclonal antibody (1:100 dilution, GeneTex, Irvine, CA) overnight at 4C in a sealed moist chamber. The slides
were washed and incubated with a goat anti-rabbit peroxidase labeled secondary antibody (1:100 dilution) for 1 hr. at room temper-
ature in the dark. The slides were than washed and treated with DAB (DAB Development Kit, Vector) for 2-5 min. The slides were
washed, counterstained with hematoxylin, dehydrated and coverslipped.
Mark3 immunofluorescence
Mark3 immunofluorescence was performed in MC3T3 cells as previously described (Hebert and Stains, 2013) using a rabbit anti-
MARK3 polyclonal antibody (GeneTex). Actin was labeled by incubation of the fixed cells with 1mM TRITC-labeled phalloidin for
30 min prior to mounting. Once collected images were processed (contrast, brightness, and merged) in Adobe Photoshop CS4
(Adobe Systems, Inc, San Jose, CA).
Mark3 knockdown and quantification of osteoblast activity
For siRNA transfection experiments, primary calvarial osteoblasts were plated at 150,000 cells/well followed by transfection 24 hr
post-plating with Lipofectamine 2000 Reagent (Invitrogen) according to manufacturer’s directions with differentiation commencing
72 hr post-plating. Stealth Select RNAi siRNAs (Invitrogen) targeting Mark3 were used to knockdown its expression in calvarial os-
teoblasts (Table S4). The Stealth RNAi Negative Control Duplex (Invitrogen) was used as a scrambled control.
qPCR was used to measureMark3 gene expression. The following primer sets were used Mark3-F/Mark3-R and 36B4-F/36B4-R
(Table S4). Relative quantification was determined by the 2(-Delta Delta CT)) method using 36B4 as the reference gene (Livak and
Schmittgen, 2001).e2 Cell Systems 4, 1–14.e1–e4, January 25, 2017
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SPTBN1 and MARK3 and an Osteoblast Functional Module, Cell Systems (2016), http://dx.doi.org/10.1016/j.cels.2016.10.014Mineralized nodule formation was measured by staining cultures at 10 days post-differentiation with Alizarin Red (40 mM) (pH 5.6).
The stained cells were imaged and nodule number wasmeasured using ImageJ (NIH) (Schneider et al., 2012). Alizarin Red was quan-
tified by destaining cultures with 5% Perchloric acid and determining the optical density (405 nM) of the resulting solution against a
standard curve. All results were obtained from three independent experiments.
DEXA and mCT
At 12 and 16 weeks of age BMDwasmeasured in maleMark3tm1a(KOMP)Mbpwild-type (Mark3+/+; N = 12) andMark3tm1a(KOMP)Mbp het-
erozygous (Mark3+/; N = 18) gene trapmice using a Lunar PIXImus II Mouse Densitometer (GEMedical SystemsModel 51045; Mad-
ison, WI, USA) as described in Mesner et al. (2014). Distal femurs from 12 week old male Mark3+/+ (N = 8) and Mark3tm1a(KOMP)Mbp
homozygous gene trap mice (Mark3/; N = 13) were scanned using a vivaCT 40 imaging system (Scanco Medical) to measure
trabecular bone volume fraction and microarchitecture of the distal femur and cortical microarchitecture of the femoral midshaft.
The samples were scanned completely submerged in 95% ethanol. Scans were performed at energy level of 55 kVp and intensity
of 145 mA and an isotropic voxel size of 12.5 mm. Trabecular microarchitecture were evaluated from approximately 200 consecutive
slices of the secondary spongiosa. Cortical bone scans were performed at the midpoint of each femur. A total of 50 consecutive
slices were scanned.
Biomechanical testing
The right femurs from 12-week old maleMark3 wild-type (+/+; N = 8) and homozygous (/; N = 13) gene trap mice were loaded to
failure in four-point bending. All whole bone tests were conducted by loading the femur in the anterior to posterior direction, such that
the posterior quadrant was subjected to tensile loads. The widths of the lower and upper supports of the four-point bending appa-
ratus were 7 mm and 3 mm, respectively. Tests were conducted with a deflection rate of 0.05 mm/s using a servohydraulic materials
test system (Instron Corp., Norwood, MA). The load and mid-span deflection were acquired directly at a sampling frequency of
200 Hz. Load-deflection curves were analyzed for strength (maximum load), stiffness (the slope of the initial portion of the curve),
post-yield deflection, and total work. Femora were tested at room temperature and kept moist with phosphate buffered saline during
all tests.
QUANTIFICATION AND STATISTICAL ANALYSIS
Defining the BGIG
All analyseswere performed in the R language and environment for statistical computing (RCore Development Team, 2015). For each
of the 64 lead BMD GWAS SNPs identified by Estrada et al. (2012), we used Plink v1.9 (Chang et al., 2015) and data from the 1000
Genome Project Phase 3 (Abecasis et al., 2010) to identify proxy SNPs (r2 < 0.7). Each GWAS locus was physically defined by the
positions of the left and rightmost proxy SNPs. We then downloaded a catalog of all RefSeq transcripts from the USCS Genome
Browser (https://genome.ucsc.edu). All SNP and gene locations were relative to the hg38 genome assembly. All RefSeq transcripts
without a clear mouse homolog were removed. We then identified all remaining RefSeq genes located in or overlapping with one of
the 64 defined GWAS loci. In addition, we included the closest gene up- and downstream (based on distance to TSS). The topGO R
package (Alexa and Rahnenfuhrer, 2010) was used to measure gene ontology enrichments for the BGIG.
Identifying and characterizing enriched modules
The bone co-expression network used in this study was extensively described in Calabrese et al. (2012). To identify enriched mod-
ules, we identified mouse homologs for all BGIG genes. The module membership for each mouse homolog was determined. Some
homologs mapped to more than one module due to different microarray probes for the same gene belonging to different modules. A
Fisher’s exact test was used to identify modules with significantly (Bonferroni p < 2.33 103) enriched in BGIG genes. The topGO R
package (Alexa and Rahnenfuhrer, 2010) was used to measure gene ontology enrichments for modules 6 and 9.
Characterizing OFM genes and loci
Osteoblast gene expression profiles for OFM genes were assessed using data on purified primary calvarial osteoblasts using data
from GEO: GSE54461 and BioGPS (http://biogps.org). We used epigenomics data generated by the ENCODE and NIH Epigenom-
ics Roadmap Consortiums to quantify the overlap between lead BMD GWAS SNPs and epigenetic marks (ENCODE Project Con-
sortium et al., 2012; Kundaje et al., 2015). All data were downloaded from the Epigenomics Roadmap Consortium webportal
(http://www.roadmapepigenomics.org/data/). The data for histone modifications were downloaded as BED files in GappedPeak
format. The primary analysis used data on primary human osteoblasts. A secondary analysis comparing H3K27ac and
H3K4me2 was performing comparing all Epigenomics Roadmap samples were those modifications had been measured. The anal-
ysis of the ChromHMM generated core 15-state epigenome model used the data from primary human osteoblasts (Ernst and Kel-
lis, 2012). We downloaded dbSNP142 from the UCSC genome browser (https://genome.ucsc.edu) and 1000 sets of 30 random
SNPs selected to match the lead OFM SNPs on minor allele frequence and distance to the nearest TSS. The random SNP sets
were used to evaluate overlap at histone modification for lead OFM SNPs. To compare the expression of genes in OFM loci and
non-OFM loci we used microarray expression data from human bone biopsies described in Reppe et al. (2010); EBI ArrayExpress:
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The International Mouse Knockout Consortium (Skarnes et al., 2011) and the IMPC have generated and phenotyped mice harboring
null alleles for 4930505A04Rik (4930505A04Riktm1b(KOMP)Wtsi) (C2orf73 homolog) (N = 8 females and N = 8 males) and Sptbn1
(Sptbn1tm1a(EUCOMM)Wtsi) mutant mice (N = 7 females and N = 10 males). Phenotypes for the appropriate controls (C57BL/6) were
also collected (controls for 4930505A04Rik, N = 252 females and N = 257 males and controls for Sptbn1, N = 777 females and
N = 814 males). A description of the battery of phenotypes collected on mutants can be found at (http://www.mousephenotype.
org/impress/procedures/4). The mice were 14 weeks of age at DEXA scanning and both sexes for both mutants were included.
We downloaded raw BMD, body weight and metadata for both mutants from the IMPC webportal (http://www.mousephenotype.
org). These data were analyzed using the PhenStat R package (Kurbatova et al., 2015). PhenStat was developed to analyze data
generated by the IMPC inwhich a large number of wild-type controls are phenotyped across awide-time range in batches and exper-
imental mutant animals are tested in small groups interspersed among wild-type batches. We used the Mixed Model framework in
PhenStat to analyze BMD data on the mutants. The mixed model framework starts with a full model (with fixed effects of genotype,
sex, genotype x sex and weight and batch as a random effect) and ends with final reduced model and genotype effect evaluation
procedures (Kurbatova et al., 2015; West et al., 2014).
Analysis of GTEx data
We queried GTEx for eQTL results for all genes in the Chr. 2q16.2 and Chr. 14q32.32 BMDGWAS regions. A description of the GTEx
eQTL analysis methods can be found at (http://www.gtexportal.org/home/). Results from the version 6 analyses for all significant
SNP expression pairs were downloaded from the GTEx web portal (http://www.gtexportal.org/home/) and used for downstream an-
alyses. The ‘‘coloc’’ R package was used for the Bayesian localization analysis using default parameters (Giambartolomei et al.,
2014).
Additional statistical analysis
The results of the siRNA analysis between groups were compared using the Student’s t test. Phenotypic data in Mark3 mutant and
wild-typemice were analyzed using the lsmeans R package (Lenth, 2016). Input for the lsmeans function was a linear model including
terms for genotype and weight at sacrifice. Weight at sacrifice was a significant covariate for all evaluated bone phenotypes. Values
reported were means ± SEM for siRNA experiments and lsmeans ± SEM for bone phenotypes. Comparisons at p < 0.05 were
deemed significant.
DATA AND SOFTWARE AVAILABILITY
The R script used for generating the BGIG and network mapping is available from https://github.com/charlesfarber/GWAS_
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